Matches in Nanopublications for { ?s ?p "[We identified TET2 deletions in 50/893 patients (26 males, 24 females; 44-87 years) resulting in a 5.6% frequency [22/425 AML (5.2%), 15/217 chronic myelomonocytic leukaemia (CMML; 6.9%), 9/188 myelodysplastic syndromes (4.8%), 4/63 myeloproliferative neoplasms (6.3%)].]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 8 of
8
with 100 items per page.
- NP208346.RAwUJyjSKfFOzUACveu5htR5zHPkcVVdTe5eD9Bm7Ro5g130_assertion description "[We identified TET2 deletions in 50/893 patients (26 males, 24 females; 44-87 years) resulting in a 5.6% frequency [22/425 AML (5.2%), 15/217 chronic myelomonocytic leukaemia (CMML; 6.9%), 9/188 myelodysplastic syndromes (4.8%), 4/63 myeloproliferative neoplasms (6.3%)].]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP208346.RAwUJyjSKfFOzUACveu5htR5zHPkcVVdTe5eD9Bm7Ro5g130_provenance.
- NP203797.RA9oaz6-FbAAqzJyK7MFCwfawAi04J1i7swLdp4BKA-rE130_assertion description "[We identified TET2 deletions in 50/893 patients (26 males, 24 females; 44-87 years) resulting in a 5.6% frequency [22/425 AML (5.2%), 15/217 chronic myelomonocytic leukaemia (CMML; 6.9%), 9/188 myelodysplastic syndromes (4.8%), 4/63 myeloproliferative neoplasms (6.3%)].]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP203797.RA9oaz6-FbAAqzJyK7MFCwfawAi04J1i7swLdp4BKA-rE130_provenance.
- assertion description "[We identified TET2 deletions in 50/893 patients (26 males, 24 females; 44-87 years) resulting in a 5.6% frequency [22/425 AML (5.2%), 15/217 chronic myelomonocytic leukaemia (CMML; 6.9%), 9/188 myelodysplastic syndromes (4.8%), 4/63 myeloproliferative neoplasms (6.3%)].]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[We identified TET2 deletions in 50/893 patients (26 males, 24 females; 44-87 years) resulting in a 5.6% frequency [22/425 AML (5.2%), 15/217 chronic myelomonocytic leukaemia (CMML; 6.9%), 9/188 myelodysplastic syndromes (4.8%), 4/63 myeloproliferative neoplasms (6.3%)].]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[We identified TET2 deletions in 50/893 patients (26 males, 24 females; 44-87 years) resulting in a 5.6% frequency [22/425 AML (5.2%), 15/217 chronic myelomonocytic leukaemia (CMML; 6.9%), 9/188 myelodysplastic syndromes (4.8%), 4/63 myeloproliferative neoplasms (6.3%)].]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[We identified TET2 deletions in 50/893 patients (26 males, 24 females; 44-87 years) resulting in a 5.6% frequency [22/425 AML (5.2%), 15/217 chronic myelomonocytic leukaemia (CMML; 6.9%), 9/188 myelodysplastic syndromes (4.8%), 4/63 myeloproliferative neoplasms (6.3%)].]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- NP932714.RAMjP85K8oqETF2-z4S3bqxPw5G64NIGfMEt_Rywe3Z3M130_assertion description "[We identified TET2 deletions in 50/893 patients (26 males, 24 females; 44-87 years) resulting in a 5.6% frequency [22/425 AML (5.2%), 15/217 chronic myelomonocytic leukaemia (CMML; 6.9%), 9/188 myelodysplastic syndromes (4.8%), 4/63 myeloproliferative neoplasms (6.3%)].]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP932714.RAMjP85K8oqETF2-z4S3bqxPw5G64NIGfMEt_Rywe3Z3M130_provenance.
- NP914054.RA_8K8MGvKy6BfU7k9WVPlGP1QgJwX6O_0CC6mWlrytxw130_assertion description "[We identified TET2 deletions in 50/893 patients (26 males, 24 females; 44-87 years) resulting in a 5.6% frequency [22/425 AML (5.2%), 15/217 chronic myelomonocytic leukaemia (CMML; 6.9%), 9/188 myelodysplastic syndromes (4.8%), 4/63 myeloproliferative neoplasms (6.3%)].]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP914054.RA_8K8MGvKy6BfU7k9WVPlGP1QgJwX6O_0CC6mWlrytxw130_provenance.